Zacks: Brokerages Anticipate Inogen, Inc (INGN) to Announce $0.29 EPS
Brokerages expect Inogen, Inc (NASDAQ:INGN) to report earnings per share of $0.29 for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Inogen’s earnings, with the lowest EPS estimate coming in at $0.24 and the highest estimate coming in at $0.33. Inogen reported earnings per share of $0.16 during the same quarter last year, which indicates a positive year-over-year growth rate of 81.3%. The company is expected to issue its next earnings results on Thursday, November 2nd.
According to Zacks, analysts expect that Inogen will report full year earnings of $1.20 per share for the current fiscal year, with EPS estimates ranging from $1.17 to $1.23. For the next financial year, analysts forecast that the business will post earnings of $1.30 per share, with EPS estimates ranging from $1.23 to $1.39. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Inogen.
Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.28 by $0.10. The company had revenue of $64.10 million during the quarter, compared to analysts’ expectations of $59.99 million. Inogen had a return on equity of 12.45% and a net margin of 10.36%. Inogen’s revenue for the quarter was up 17.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.25 EPS.
Several research firms have recently commented on INGN. Piper Jaffray Companies reissued a “hold” rating and set a $90.00 target price on shares of Inogen in a research report on Tuesday. Needham & Company LLC reissued a “buy” rating and set a $108.00 target price on shares of Inogen in a research report on Friday, September 1st. BidaskClub downgraded shares of Inogen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Zacks Investment Research downgraded shares of Inogen from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Finally, J P Morgan Chase & Co boosted their target price on shares of Inogen to $102.00 and gave the stock an “overweight” rating in a research report on Monday, June 26th. Four equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Inogen currently has a consensus rating of “Buy” and an average target price of $91.33.
Shares of Inogen (NASDAQ INGN) traded down 2.00% during trading on Friday, hitting $101.52. The stock had a trading volume of 98,605 shares. The company has a market capitalization of $2.10 billion, a P/E ratio of 88.12 and a beta of 1.02. The firm has a 50-day moving average of $95.76 and a 200 day moving average of $87.16. Inogen has a 1-year low of $50.24 and a 1-year high of $104.88.
In other Inogen news, EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction dated Tuesday, July 18th. The shares were sold at an average price of $94.21, for a total value of $235,525.00. Following the completion of the sale, the executive vice president now directly owns 4,833 shares of the company’s stock, valued at approximately $455,316.93. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Raymond Huggenberger sold 14,000 shares of the company’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $91.67, for a total transaction of $1,283,380.00. Following the completion of the sale, the director now directly owns 7,808 shares of the company’s stock, valued at $715,759.36. The disclosure for this sale can be found here. Insiders sold a total of 44,667 shares of company stock valued at $4,170,776 over the last ninety days. 5.31% of the stock is currently owned by insiders.
A number of hedge funds have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd bought a new stake in Inogen in the 2nd quarter worth about $442,000. Koch Industries Inc. grew its position in Inogen by 19,485.8% in the 2nd quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock worth $650,000 after purchasing an additional 653,747 shares in the last quarter. Verition Fund Management LLC bought a new stake in Inogen in the 2nd quarter worth about $280,000. Piedmont Investment Advisors LLC bought a new stake in Inogen in the 2nd quarter worth about $336,000. Finally, Ameritas Investment Partners Inc. grew its position in Inogen by 6.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock worth $143,000 after purchasing an additional 86 shares in the last quarter.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.